Factors Affecting Surgical Treatment With Infliximab Therapy in Perianal Fistula With Crohn Disease.
Factors Affecting Surgical Treatment With Infliximab Therapy in Perianal Fistula With Crohn Disease. Ann Coloproctol. 2019 Oct;35(5):225-226 Authors: Lee JL PMID: 31725995 [PubMed]
AbstractOsteopenia and osteoporosis are common features in inflammatory bowel disease (IBD), comprising both Crohn ’s disease and ulcerative colitis. Moreover, Crohn’s disease is associated with increased fracture risk. The etiology of bone loss in IBD is multifactorial. It includes insufficient intake or absorption of calcium, vitamin D, and potassium; smoking; a low peak bone mass; a low body mass index; a nd decreased physical activity. In several studies, it has been shown that elevated concentrations of systemic and local pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), inte...
ABSTRACT: The lifelong, chronic nature of Crohn's disease produces incessant stress that affects individuals physically, emotionally, and socially. Coping with the symptoms and treatment is improved when persons engage their faith and spiritual resources. Clear understanding of the physical and emotional aspects of Crohn's can support a person's ability to manage the disease. Knowledge of emerging treatments also provides nurses with hopeful input to share with their patients.
The efficacy of antibody-based therapeutics depends on their pharmacokinetics. The pharmacokinetic and exposure response profiles of ustekinumab, a monoclonal antibody against interleukin 12/interleukin 23, are known in patients with Crohn ’s disease, yet there are few data from patients with ulcerative colitis. We characterized ustekinumab’s pharmacokinetics, exposure response, and optimal serum concentrations in patients with ulcerative colitis.
We present the case of a 39-year-old male treated with Etanercept and debut of inflammatory bowel disease 11 months later. A literature review of the possible relationship between the debut and the treatment with Etanercept is done. PMID: 31793319 [PubMed - as supplied by publisher]
Conditions: Intestinal Disorder; Inflammatory Bowel Diseases; Crohn Disease Intervention: Other: acupuncture Sponsors: Shanghai Institute of Acupuncture, Moxibustion and Meridian; Fudan University; Shanghai University of Traditional Chinese Medicine; Shanghai Jiao Tong University School of Medicine; Indiana University School of Medicine Recruiting
ConclusionsIL-17 contributes to the pathogenesis of intestinal fibrosis, and anti-IL-17 therapy may weaken this effect by downregulating expression of profibrogenic cytokines and disturbing the MMP/TIMPs balance.
Drug therapies and the postoperative management of patients will be in the spotlight at the upcoming Advances in Inflammatory Bowel Diseases conference.Medscape Medical News
Conditions: Crohn Disease; Pediatric Crohns Disease Interventions: Drug: Azithromycin; Drug: Metronidazole; Other: Standard of Care Sponsors: University of North Carolina, Chapel Hill; Crohn's and Colitis Foundation; University of Amsterdam Not yet recruiting
Conclusions: The high prevalence of psychological disorders and malnutrition were found in IBD patients, and thereby negatively affect QoL. Disease activity was significantly associated with psychological disorders, risk of malnutrition and impaired QoL. And avoiding certain foods was related to risk of malnutrition. PMID: 31791216 [PubMed - as supplied by publisher]
Which endoscopic procedure best identifies neoplasia in patients with ulcerative colitis or Crohn disease?Alimentary Pharmacology &Therapeutics